A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors.
J. Berlin
Research Funding - Pfizer
V. L. Keedy
No relevant relationships to disclose
P. A. Janne
No relevant relationships to disclose
L. Yee
No relevant relationships to disclose
N. A. Rizvi
No relevant relationships to disclose
X. Jin
Employment or Leadership Position - Daiichi Sankyo (U)
Stock Ownership - Daiichi Sankyo
C. Copigneaux
Employment or Leadership Position - Daiichi Sankyo
Stock Ownership - Daiichi Sankyo
Research Funding - Daiichi Sankyo
T. Hettmann
Employment or Leadership Position - U3Pharma
D. M. Beaupre
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
P. LoRusso
Consultant or Advisory Role - Daiichi Sankyo (U)
Research Funding - Daiichi Sankyo